Exciting News from GlyTherix at JPM Healthcare Week 2025!
We’re thrilled to announce that GlyTherix, a leader in targeted radiotherapy, will be showcasing its cutting-edge technology at two major events during JPM Healthcare Week in San Francisco.
Wuxi Apptec Global Forum (Jan 14): CEO Dr. Brad Walsh will lead an Executive Roundtable on GlyTherix’s innovative targeted radiotherapy, discussing its potential to revolutionize cancer treatment.
Biotech Showcase 2025 (Jan 13-15): Dr. Walsh will also join a panel on “Collaboration Opportunities & Scientific Engagement in the Asia-Pacific Region” alongside other biotech leaders. This event brings together over 400 presenting companies and thousands of investors.
Strategic Advancements: We’ve made significant strides in our supply chain, securing new alpha & beta isotope supply agreements with Eckert & Ziegler and Nusano to support the clinical development of our radiotherapy programs, bringing our international supplier & manufacturing agreements to seven in total.
Celebrating Success: A huge congratulations to Dr. Elcin Zan, a member of our Clinical Advisory Panel, on her appointment as Chair of Nuclear Medicine at the Cleveland Clinic! Dr. Zan’s expertise continues to be invaluable in advancing our mission to improve cancer treatment outcomes.
We’re excited to meet with potential partners and investors during JPM Healthcare Week to further our vision of precision cancer therapies that enhance patient care and outcomes.
Read the full press release here: GlyTherix-Update-Press-Release-10-Jan-25-Final.pdf